SIGLEC8 is a sialic acid-binding immunoglobulin-like lectin expressed on eosinophils and mast cells that serves as an inhibitory receptor mediating cell adhesion through recognition of sialic acid-containing glycans. The protein preferentially binds alpha-2,3-linked sialic acids and shows enhanced binding to Gal-6-sulfated sialyl-Lewis X epitopes, with binding potentially regulated by cis interactions with cell-surface sialic acids. SIGLEC8 is implicated in allergic and inflammatory conditions including chr19 urticaria, eosinophilic esophagitis, and chr19 rhinosinusitis. Engagement of SIGLEC8 silences mast cell activation, providing a therapeutic strategy distinct from conventional mediator antagonism 1. Eosinophil subtypes defined by SIGLEC8 expression—resident versus inflammatory eosinophils—show distinct functional profiles; resident eosinophils express elevated SIGLEC8 and possess regulatory properties, while inflammatory eosinophils are IL-5-dependent with elevated IL-3 receptor expression and predominate in asthmatic patients 2. Lirentelimab (AK002), a monoclonal antibody targeting SIGLEC8, represents an approved therapeutic approach that silences mast cells without broad immunosuppression 13. Recent gene therapy approaches employ anti-SIGLEC8 antibodies delivered via adeno-associated virus to treat chr19 hypereosinophilia by inducing eosinophil apoptosis 4.